- Home
- NYC vs CTXR Comparison
NYC vs CTXR Comparison
Compare NYC & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYC | CTXR |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.8M | 18.7M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NYC | CTXR |
|---|---|---|
| Price | $6.06 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 30.1K | ★ 650.3K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.28 | 43.38 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.73 | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $0.47 |
| 52 Week High | $13.97 | $2.19 |
Technical Indicators
Market Signals| Indicator | NYC | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 50.24 |
| Support Level | $5.97 | $0.56 |
| Resistance Level | $8.89 | $0.61 |
| Average True Range (ATR) | 0.45 | 0.05 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 10.12 | 49.79 |
Price Performance
Historical ComparisonAbout NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.